Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 4/10/2026 | $30.00 | Sell | Goldman | |
| 3/25/2026 | Underperform → Mkt Perform | Raymond James | ||
| 3/6/2026 | $8.00 | Overweight → Equal Weight | Barclays | |
| 2/27/2026 | $10.00 | Buy → Hold | Craig Hallum | |
| 1/26/2026 | $100.00 | Overweight | Analyst | |
| 1/6/2026 | $13.00 | Market Perform → Outperform | Leerink Partners | |
| 11/21/2025 | $10.00 | Buy | Rothschild & Co Redburn | |
| 11/13/2025 | $9.00 | Market Perform | BMO Capital Markets |
Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to be provided upon transaction close RADNOR, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for a consideration of up to $135 million. The transaction is expected to close during the second quarter of 2026 subject to customary closing conditions. "Certara's strategy is centered on expanding the scale, reach, and impact of our MIDD and Clinical Intelligence solutions," sai
CVR Energy, Inc. (NYSE:CVI) plans to release its first quarter 2026 earnings results on Wednesday, April 29, after the close of trading on the New York Stock Exchange. The Company also will host a teleconference call on Thursday, April 30, at 1 p.m. Eastern to discuss these results. This call, which will contain forward-looking information, will be webcast live and can be accessed on the Investor Relations section of CVR Energy's website at www.CVREnergy.com. For investors or analysts who want to participate during the call, the dial-in number is (800) 715-9871, conference ID 3388257. A repeat of the call can be accessed for seven days by dialing (800) 770-2030, conference ID 3388257. The
RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulat
Goldman resumed coverage of CVR Energy with a rating of Sell and set a new price target of $30.00
Raymond James upgraded CVR Energy from Underperform to Mkt Perform
Barclays downgraded Certara from Overweight to Equal Weight and set a new price target of $8.00
4 - EXPONENT INC (0000851520) (Issuer)
4 - EXPONENT INC (0000851520) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
8-K - Certara, Inc. (0001827090) (Filer)
DEFA14A - CVR ENERGY INC (0001376139) (Filer)
DEF 14A - CVR ENERGY INC (0001376139) (Filer)
4 - CVR ENERGY INC (0001376139) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
4 - CVR ENERGY INC (0001376139) (Issuer)
MENLO PARK, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (NASDAQ:EXPO), a leading engineering and scientific consulting firm, today announced its appointment of John Pye to President and Eric Anderson to Chief Financial Officer, both effective May 1, 2026 and reporting to Catherine Corrigan, Chief Executive Officer; nomination of Richard Schlenker, Executive Vice President and current Chief Financial Officer to stand for election to the Board of Directors; and the appointment of Karen Richardson as Chairman of the Board upon the retirement of Paul Johnston effective as of the Annual Meeting of Stockholders to be held on June 4, 2026. Dr. Pye joined Exponent in 1999, was promo
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara's Board of Directors, effective January 1, 2026, succeeding William F. Feehery, who will at that point serve as an external advisor during a transition period. Resnick brings over 20 years of experience with IQVIA, a g
RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology. Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data
CVR Energy, Inc. (NYSE:CVI) plans to release its first quarter 2026 earnings results on Wednesday, April 29, after the close of trading on the New York Stock Exchange. The Company also will host a teleconference call on Thursday, April 30, at 1 p.m. Eastern to discuss these results. This call, which will contain forward-looking information, will be webcast live and can be accessed on the Investor Relations section of CVR Energy's website at www.CVREnergy.com. For investors or analysts who want to participate during the call, the dial-in number is (800) 715-9871, conference ID 3388257. A repeat of the call can be accessed for seven days by dialing (800) 770-2030, conference ID 3388257. The
RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulat
MENLO PARK, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (NASDAQ:EXPO), today announced that it will report First Quarter of fiscal year 2026 financial results for the period ended April 3, 2026 following the close of the market on Thursday, April 30, 2026. On that day, Dr. Catherine Corrigan, Chief Executive Officer and President, and Richard Schlenker, Executive Vice President and Chief Financial Officer, will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the Company's business and financial results. Event:Exponent, Inc. First Quarter of Fiscal Year 2026 Financial Results Conference CallDate:Thursday, April 30, 2026Time:4:30 p.m. Eastern Time /
SC 13D/A - CVR ENERGY INC (0001376139) (Subject)
SC 13G - Certara, Inc. (0001827090) (Subject)
SC 13D/A - CVR ENERGY INC (0001376139) (Subject)